Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex vs Neostigmine for Neuromuscular Blockade Reversal
NCT02243943Phase 4Completed
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2014
- Primary completion
- Apr 2016
- Modality
- Biodegradable Polymers, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Mean Lowest Oxygen Saturation. Started Sep 2014; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT02243943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02243943.